AU2003228593B2 - Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt - Google Patents

Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt Download PDF

Info

Publication number
AU2003228593B2
AU2003228593B2 AU2003228593A AU2003228593A AU2003228593B2 AU 2003228593 B2 AU2003228593 B2 AU 2003228593B2 AU 2003228593 A AU2003228593 A AU 2003228593A AU 2003228593 A AU2003228593 A AU 2003228593A AU 2003228593 B2 AU2003228593 B2 AU 2003228593B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
ester
alpha
acid
ketoalkanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2003228593A
Other languages
English (en)
Other versions
AU2003228593A1 (en
Inventor
Mitchell P Fink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi USA Inc
Original Assignee
Critical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc filed Critical Critical Therapeutics Inc
Publication of AU2003228593A1 publication Critical patent/AU2003228593A1/en
Application granted granted Critical
Publication of AU2003228593B2 publication Critical patent/AU2003228593B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003228593A 2002-04-17 2003-04-17 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt Expired - Fee Related AU2003228593B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37368002P 2002-04-17 2002-04-17
US60/373,680 2002-04-17
PCT/US2003/012134 WO2003088955A1 (en) 2002-04-17 2003-04-17 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt

Publications (2)

Publication Number Publication Date
AU2003228593A1 AU2003228593A1 (en) 2003-11-03
AU2003228593B2 true AU2003228593B2 (en) 2006-07-27

Family

ID=29251059

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003228593A Expired - Fee Related AU2003228593B2 (en) 2002-04-17 2003-04-17 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt
AU2003230996A Abandoned AU2003230996A1 (en) 2002-04-17 2003-04-17 Method for treating ileus with an alpha-ketoalkanoic acid or - ester or - amide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003230996A Abandoned AU2003230996A1 (en) 2002-04-17 2003-04-17 Method for treating ileus with an alpha-ketoalkanoic acid or - ester or - amide

Country Status (8)

Country Link
US (2) US20030232884A1 (https=)
EP (2) EP1496883A1 (https=)
JP (2) JP2005527592A (https=)
AT (1) ATE306257T1 (https=)
AU (2) AU2003228593B2 (https=)
CA (2) CA2481749A1 (https=)
DE (1) DE60301878T2 (https=)
WO (2) WO2003088956A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002563A2 (en) * 2003-06-13 2005-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Eduction Method for treating alcoholic hepatitis
US7464564B2 (en) * 2003-09-22 2008-12-16 Dippin' Dots, Inc. Method and apparatus for combining cookie dough and ice cream
US20050106301A1 (en) * 2003-09-24 2005-05-19 Curt Jones Method and apparatus for cryogenically manufacturing ice cream
EP1689431A4 (en) * 2003-10-27 2010-11-17 Univ Pennsylvania CYTOPROTECTIVE EFFECTS OF ETHYL PYRUVATE
US7316122B1 (en) 2004-01-06 2008-01-08 Dippin' Dots, Inc. Tray for producing particulate food products
US20060062877A1 (en) * 2004-09-21 2006-03-23 Curt Jones Method and apparatus for storing food products
US20060093719A1 (en) * 2004-11-01 2006-05-04 Dippin' Dots, Inc. Particulate ice cream dot sandwich
US20060093714A1 (en) * 2004-11-01 2006-05-04 Dippin' Dots, Inc. Particulate ice cream dot cake
WO2006108679A2 (en) * 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
US7332315B2 (en) * 2005-08-17 2008-02-19 Colgate-Palmolive Company Method to remove bisulfite by-products from enzyme compositions
US20070134394A1 (en) * 2005-12-12 2007-06-14 Dippin' Dots, Inc. Method of manufacturing particulate ice cream for storage in conventional freezers
US20070140044A1 (en) * 2005-12-15 2007-06-21 Dippin' Dots, Inc. Combined particulate and traditional ice cream
US20070140043A1 (en) * 2005-12-16 2007-06-21 Stan Jones Method and apparatus of combining food particles and ice cream
CN101472613A (zh) 2006-04-12 2009-07-01 R·L·亚历山大 包含丙酮酸烷基酯的组合物及其应用
US8603513B2 (en) * 2007-06-28 2013-12-10 The Procter & Gamble Company Article comprising calcium for reducing the production of TSST-1
AU2009298948B2 (en) * 2008-09-19 2013-06-20 Ferring B.V. Guanylhydrazones for treatment of postoperative intestinal inflammation
CN106727320A (zh) * 2017-01-13 2017-05-31 江苏长泰药业有限公司 一种用于修复鼻粘膜、降低过敏反应、抗炎作用的组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105783A (en) * 1975-07-23 1978-08-08 Yu Ruey J Therapeutic treatment of dry skin

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4645764A (en) * 1981-04-01 1987-02-24 Montefiore Hospital Method for preventing body fat deposition in animals
US4812479A (en) * 1981-04-01 1989-03-14 The Montefiore Hospital Society Of Western Pennsylvania, Inc. Method for preventing body fat deposition in mammals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
DE3581407D1 (de) * 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
JPS63502274A (ja) * 1985-12-18 1988-09-01 ビ−チ，リチヤ−ド　エル Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US6051609A (en) * 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
KR910000101A (ko) * 1988-06-02 1991-01-29 유다까 미시마 효소형성 억제제
US5147650A (en) * 1988-07-29 1992-09-15 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5075210A (en) * 1989-12-21 1991-12-24 The Regents Of The University Of California Preservation of the heart for transplantation
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5134162A (en) * 1990-12-24 1992-07-28 The Montefiore Hospital Association Of Western Pennsylvania Method for lowering high blood cholesterol levels in hyperlipidemic animals and confections as the ingestion medium
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5294641A (en) * 1991-11-27 1994-03-15 Montefiore - University Hospital Method for treating a medical patient for cardiac trauma
US5508308A (en) * 1992-04-16 1996-04-16 Abbott Laboratories Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
ES2157260T3 (es) * 1993-06-04 2001-08-16 Biotime Inc Solucion semejante a plasma.
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5801198A (en) * 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5667962A (en) * 1996-03-18 1997-09-16 Case Western Reserve University Pyruvate thiolester for the prevention of reperfusion injury
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
GB9724813D0 (en) * 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
DE60027319T2 (de) * 1999-10-07 2007-04-05 Xanthus Life Sciences, Inc., Montreal Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105783A (en) * 1975-07-23 1978-08-08 Yu Ruey J Therapeutic treatment of dry skin

Also Published As

Publication number Publication date
EP1494659B1 (en) 2005-10-12
EP1494659A1 (en) 2005-01-12
CA2481749A1 (en) 2003-10-30
JP2005526832A (ja) 2005-09-08
WO2003088956A8 (en) 2004-04-15
AU2003228593A1 (en) 2003-11-03
DE60301878D1 (de) 2006-02-23
ATE306257T1 (de) 2005-10-15
WO2003088956A1 (en) 2003-10-30
EP1496883A1 (en) 2005-01-19
DE60301878T2 (de) 2006-08-10
US20030232884A1 (en) 2003-12-18
JP2005527592A (ja) 2005-09-15
US20030216470A1 (en) 2003-11-20
WO2003088955A1 (en) 2003-10-30
AU2003230996A1 (en) 2003-11-03
CA2481753A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
AU2003228593B2 (en) Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt
FI92388C (fi) Menetelmä karbasykliinianalogien terapeuttisesti käyttökelpoisten syklodekstriiniklatraattien valmistamiseksi
KR101142583B1 (ko) 히알루론산 유도체 및 그것을 포함하는 약제
ES2340488T3 (es) Sales derivadas del acido lipoico y su utilizacion para el tratamiento de las enfermedades.
AU2005228685B2 (en) Hydrazide-containing CFTR inhibitor compounds and uses thereof
JP4334620B2 (ja) ヒアルロン酸の局所麻酔剤との塩からなる医薬品
CA2658361C (en) Ophthalmic formulations for the treatment of inflammation
US20040110833A1 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
JP2001507676A (ja) 抗血栓性有機硝酸塩
ES2735287T3 (es) Profármacos solubles en agua cargados positivamente de ácidos n-arilantranílicos con muy rápida velocidad de penetración en la piel
PT101165B (pt) Processo para a preparacao de inibidores duais sem sintese e sem ciclo-oxigenase
ES2498681T3 (es) Derivados de ácidos grasos con alta palatabilidad para administración oral
US4337251A (en) Method of avoiding and removing adhesions
JP2005527592A5 (https=)
JPH0291054A (ja) 新規有機ニトレート及びそれらの製造方法
CA2453433A1 (en) Methods of use for novel sulfur containing organic nitrate compounds
PT89004B (pt) Processo para a preparacao de bis-(3,5-dicarbamoil-2,4,6-tri-iodo-anilidas) de acidos dicarboxilicos substituidos e de composicoes de contraste de raios x que as contem
CA2246236C (en) Treatment and prevention of adverse effects of reactive oxygen species
PT94782A (pt) Processo para a preparacao de sais de acido n5,n10-metilen-5,6,7,8-tetrahidrofolico
ES2254190T3 (es) Remedios contra la artritis deformante.
JP2011510944A (ja) テトラヒドロピリミジンの使用
EP0402859A3 (en) Therapeutic agents of metabolic bone disease
KR100676850B1 (ko) 박테리아의 부착을 억제하는 약품의 제조와 관련된 호모시스테인 유도체의 용도
CA2346053A1 (en) Angiogenesis inhibitor
JPH01305029A (ja) テトラゾール誘導体の使用

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee